Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 641-647

  Itamochi, Hiroaki ^a,b   Yoshida, Tomokazu ^c   Walker, Cheryl Lyn ^d   Bartholomeusz, Chandra ^a   Aoki, Daisuke ^e   Ishihara, Hideki ^c   Suzuki, Nao ^e   Kigawa, Junzo ^b   Terakawa, Naoki ^b   Ueno, Naoto T ^a,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c SYSMEX CORPORATION   (Japan)

^d UNIVERSITY OF TEXAS   (United States)

^e KEIO UNIVERSITY   (Japan)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

CDK2; Cell cycle; Clear cell; Ovarian carcinoma; p27

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLINE; DOXORUBICIN; GEMCITABINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P27; PROTEIN P53; SMALL INTERFERING RNA; THREONINE;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; CELL FUNCTION; CELL NUCLEUS; CELL PROLIFERATION; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DEOXYCYTIDINE; DOXORUBICIN; ENZYME ACTIVATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION;

EID: 80051550209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.003     Document Type: Article

References (36)

1. R.E. Scully World Health Organization classification and nomenclature of ovarian cancer Natl Cancer Inst Monogr 42 1975 5 7
2. J.C. Aure, K. Hoeg, and P. Kolstad Mesonephroid tumors of the ovary. Clinical and histopathologic studies Obstet Gynecol 37 1971 860 867
3. T. Sugiyama, T. Kamura, J. Kigawa, N. Terakawa, Y. Kikuchi, and T. Kita Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2000 2584 2589 (Pubitemid 30331967)
4. M. Takano, Y. Kikuchi, N. Yaegashi, K. Kuzuya, M. Ueki, and H. Tsuda Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging Br J Cancer 94 2006 1369 1374 (Pubitemid 43772268)
5. H. Itamochi, J. Kigawa, T. Sugiyama, Y. Kikuchi, M. Suzuki, and N. Terakawa Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary Obstet Gynecol 100 2002 281 287 (Pubitemid 34874791)
6. C.J. Sherr G1 phase progression: cycling on cue Cell 79 1994 551 555 (Pubitemid 24363798)
7. J. Massague G1 cell-cycle control and cancer Nature 432 2004 298 306 (Pubitemid 39551657)
8. C.J. Sherr, and J.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 13 1999 1501 1512 (Pubitemid 29297917)
9. H. Ishihara, T. Yoshida, Y. Kawasaki, H. Kobayashi, M. Yamasaki, and S. Nakayama A new cancer diagnostic system based on a CDK profiling technology Biochim Biophys Acta 1741 2005 226 233 (Pubitemid 41338667)
10. S.J. Kim, S. Nakayama, Y. Miyoshi, T. Taguchi, Y. Tamaki, and T. Matsushima Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer Ann Oncol 19 2008 68 72
11. Y. Jiang, R.C. Zhao, and C.M. Verfaillie Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity Proc Natl Acad Sci U S A 97 2000 10538 10543
12. G. Viglietto, M.L. Motti, P. Bruni, R.M. Melillo, A. D'Alessio, and D. Califano Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer Nat Med 8 2002 1136 1144 (Pubitemid 35175969)
13. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, and K. Han PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat Med 8 2002 1153 1160 (Pubitemid 35175971)
14. M.D. Larrea, S.A. Wander, and J.M. Slingerland p27 as Jekyll and Hyde: regulation of cell cycle and cell motility Cell Cycle 8 2009 3455 3461
15. I. Reynisdottir, K. Polyak, A. Iavarone, and J. Massague Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta Genes Dev 9 1995 1831 1845
16. C. Catzavelos, N. Bhattacharya, Y.C. Ung, J.A. Wilson, L. Roncari, and C. Sandhu Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nat Med 3 1997 227 230 (Pubitemid 27064710)
17. J. Slingerland, and M. Pagano Regulation of the cdk inhibitor p27 and its deregulation in cancer J Cell Physiol 183 2000 10 17 (Pubitemid 30130220)
18. M. Loda, B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, and G.F. Draetta Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nat Med 3 1997 231 234 (Pubitemid 27064711)
19. I.M. Chu, L. Hengst, and J.M. Slingerland The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature reviews Cancer 8 2008 253 267 (Pubitemid 351430863)
20. D.G. Rosen, G. Yang, K.Q. Cai, R.C. Bast Jr., D.M. Gershenson, and E.G. Silva Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer Clin Cancer Res 11 2005 632 637 (Pubitemid 40116889)
21. A. Psyrri, A. Bamias, Z. Yu, P.M. Weinberger, M. Kassar, and S. Markakis Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer Clin Cancer Res 11 2005 8384 8390 (Pubitemid 41746951)
22. B. Vanhaesebroeck, and D.R. Alessi The PI3K-PDK1 connection: more than just a road to PKB Biochem J 346 Pt 3 2000 561 576 (Pubitemid 30171014)
23. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501 (Pubitemid 37328931)
24. M.S. van der Heijden, and R. Bernards Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 16 2010 3094 3099
25. I. Shin, F.M. Yakes, F. Rojo, N.Y. Shin, A.V. Bakin, and J. Baselga PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization Nat Med 8 2002 1145 1152 (Pubitemid 35175970)
26. R.H. Medema, G.J. Kops, J.L. Bos, and B.M. Burgering AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 Nature 404 2000 782 787 (Pubitemid 30212408)
27. S.M. Keenan, C. Bellone, and J.J. Baldassare Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase J Biol Chem 276 2001 22404 22409
28. W.A. Bresnahan, I. Boldogh, T. Ma, T. Albrecht, and E.A. Thompson Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle Cell Growth Differ 7 1996 1283 1290 (Pubitemid 26360677)
29. E.S. Yang, and K.L. Burnstein Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm J Biol Chem 278 2003 46862 46868 (Pubitemid 37452267)
30. R.E. Herrera, V.P. Sah, B.O. Williams, T.P. Makela, R.A. Weinberg, and T. Jacks Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts Mol Cell Biol 16 1996 2402 2407 (Pubitemid 26123762)
31. H.C. Hwang, and B.E. Clurman Cyclin E in normal and neoplastic cell cycles Oncogene 24 2005 2776 2786 (Pubitemid 40638089)
32. J. Farley, L.M. Smith, K.M. Darcy, E. Sobel, D. O'Connor, and B. Henderson Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study Cancer Res 63 2003 1235 1241 (Pubitemid 36348700)
33. D.G. Rosen, G. Yang, M.T. Deavers, A. Malpica, J.J. Kavanagh, and G.B. Mills Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma Cancer 106 2006 1925 1932 (Pubitemid 43673207)
34. T. Takahashi, F. Yamasaki, T. Sudo, H. Itamochi, S. Adachi, and M. Tamamori-Adachi Cyclin A-associated kinase activity is needed for paclitaxel sensitivity Mol Cancer Ther 4 2005 1039 1046 (Pubitemid 41079097)
35. P.M. Price, F. Yu, P. Kaldis, E. Aleem, G. Nowak, and R.L. Safirstein Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2 J Am Soc Nephrol 17 2006 2434 2442 (Pubitemid 44300959)
36. M. Hamdi, H.E. Popeijus, F. Carlotti, J.M. Janssen, C. van der Burgt, and P. Cornelissen-Steijger ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses DNA Repair (Amst) 7 2008 487 496